Published August 9, 2024 | Version v1
Journal article Open

A Protocol for the Inclusion of Minoritized Persons in Alzheimer Disease Research From the ADNI3 Diversity Taskforce

  • 1. University of Wisconsin
  • 2. Fordham University
  • 3. Department of Veterans Affairs Medical Center
  • 4. University of Southern California
  • 5. San Francisco Veteran's Administration Medical Center
  • 6. Icahn School of Medicine at Mount Sinai
  • 7. Washington University in Saint Louis
  • 8. University of California, Los Angeles
  • 9. Duke University
  • 10. Mount Sinai Medical Center
  • 11. Indiana University Health
  • 12. Mount Sinai School of Medicine
  • 13. Medical University of South Carolina
  • 14. MindX Sciences Inc.
  • 15. University of Chicago

Description

Importance: Black or African American (hereinafter, Black) and Hispanic or Latino/a/x (hereinafter, Latinx) adults are disproportionally affected by Alzheimer disease, but most research studies do not enroll adequate numbers of both of these populations. The Alzheimer's Disease Neuroimaging Initiative-3 (ADNI3) launched a diversity taskforce to pilot a multipronged effort to increase the study inclusion of Black and Latinx older adults.

Objective: To describe and evaluate the culturally informed and community-engaged inclusion efforts to increase the screening and enrollment of Black and Latinx older adults in ADNI3.

Design, Setting, and Participants: This cross-sectional study used baseline data from a longitudinal, multisite, observational study conducted from January 15, 2021, to July 12, 2022, with no follow-up. The study was conducted at 13 ADNI3 sites in the US. Participants included individuals aged 55 to 90 years without cognitive impairment and those with mild cognitive impairment or Alzheimer disease.

Exposures: Efforts included (1) launch of an external advisory board, (2) changes to the study protocol, (3) updates to the digital prescreener, (4) selection and deployment of 13 community-engaged research study sites, (5) development and deployment of local and centralized outreach efforts, and (6) development of a community-science partnership board.

Main Outcomes and Measures: Screening and enrollment numbers from centralized and local outreach efforts, digital advertisement metrics, and digital prescreener completion.

Results: A total of 91 participants enrolled in the trial via centralized and local outreach efforts, of which 22 (24.2%) identified as Latinx and 55 (60.4%) identified as Black (median [IQR] age, 65.6 [IQR, 61.5-72.5] years; 62 women [68.1%]). This represented a 267.6% increase in the monthly rate of enrollment (before: 1.11 per month; during: 4.08 per month) of underrepresented populations. For the centralized effort, social media advertisements were run between June 1, 2021, and July 31, 2022, which resulted in 2079 completed digital prescreeners, of which 1289 met criteria for subsequent site-level screening. Local efforts were run between June 1, 2021, to July 31, 2022. A total of 151 participants underwent site-level screening (100 from local efforts, 41 from centralized efforts, 10 from other sources).

Conclusions and Relevance: In this cross-sectional study of pilot inclusion efforts, a culturally informed, community-engaged approach increased the inclusion of Black and Latinx participants in an Alzheimer disease cohort study.

Notes

Due to the large number of authors, only the first 20 and the University of Chicago authors are included on the above author list. Please download the article for the complete list of authors.

Data availability

See Supplement 2.

Files

okonkwo_2024_oi_240838_1722613151.62307.pdf

Files (1.6 MB)

Name Size Download all
Article
md5:1eec8b085ba5f188c527c4d55c0a435b
1.2 MB Preview Download
Supplemental files
md5:9703b20a86a3322cb9e02ead5effcdc6
429.2 kB Preview Download

Additional details

Identifiers

DOI
10.1001/jamanetworkopen.2024.27073
Other
oai:uchicago.tind.io:13373

Funding

National Institute on Aging
U19AG024904
National Institutes of Health
Alzheimer’s Disease Neuroimaging Initiative
Department of Defense
W81XWH-12-2-0012
National Institute of Biomedical Imaging and Bioengineering
AbbVie
Alzheimer's Association
Alzheimer's Drug Discovery Foundation
Araclon Biotech
BioClinica Inc
Biogen
Bristol-Myers Squibb Co
CereSpir Inc
Cogstate
Eisai Inc
Elan Pharmaceuticals Inc
Eli Lilly and Co
EuroImmun
F. Hoffmann-La Roche Ltd
Genentech Inc
Fujirebio
GE Healthcare
IXICO Ltd
Janssen Alzheimer Immunotherapy Research & Development LLC
Johnson & Johnson Pharmaceutical Research & Development LLC
Lumosity
Lundbeck
Merck & Co Inc
Meso Scale Diagnostics LLC
NeuroRx Research
Neurotrack Technologies
Novartis Pharmaceuticals Corp
Pfizer Inc
Piramal Imaging
Servier
Takeda Pharmaceutical Co
Transition Therapeutics
Canadian Institutes of Health Research

UChicago Information

Division(s)
Biological Sciences Division
Department(s)
Neurology